Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 2/20 | 0.36 |
| ▸ | CASP3 | P42574 | 5/20 | 0.35 |
| ▸ | CASP7 | P55210 | 4/20 | 0.35 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | CASP9 | P55211 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6137742 | 1.00 | VCAM1 (0.36) | VCAM1CASP3CASP7NPBWR1MCHR1 | |
| SCHEMBL2768514 | 1.00 | VCAM1 (0.36) | VCAM1CASP3CASP7NPBWR1MCHR1 | |
| SCHEMBL6139039 | 0.90 | CASP3 (0.35) | VCAM1CASP3CASP7NPBWR1MCHR1 | |
| SCHEMBL2768975 | 0.90 | CASP3 (0.35) | VCAM1CASP3CASP7NPBWR1MCHR1 | |
| SCHEMBL2769590 | 0.90 | CASP3 (0.35) | VCAM1CASP3CASP7NPBWR1MCHR1 | |
| SCHEMBL6138091 | 0.84 | HDAC8 (0.37) | CASP3CASP7HDAC8HDAC6HDAC1 | |
| SCHEMBL2767458 | 0.84 | HDAC8 (0.37) | CASP3CASP7HDAC8HDAC6HDAC1 | |
| SCHEMBL6564147 | 0.84 | CASP3 (0.45) | CASP3CASP7CASP9KMT2AALDH1A1 | |
| SCHEMBL2769019 | 0.84 | HDAC8 (0.37) | CASP3CASP7HDAC8HDAC6HDAC1 | |
| SCHEMBL2768886 | 0.76 | ALDH1A1 (0.41) | KMT2AALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272175-B1 | N,N'-DIARYL GUANIDINES AS IL-8 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE LLC (US) | 2010-04-21 | — | — | EP | disclosed |
| EP-1272175-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1261329-A4 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6680317-B2 | N-(PHENYL)-N*-(2-HYDROXY-3-AMINOSULFONYLPHENYL)GUANIDINE DERIVATIVES; CHEMOKINE INHIBITORS; RESPIRATORY, CARDIOVASCULAR, RHEUMATIC, BRAIN, AND NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2004-01-20 | — | — | US | disclosed |
| US-20030216375-A1 | Il-8 receptor anatagonists | GLAXOSMITHKLINE LLC | 2003-11-20 | — | — | US | disclosed |
| US-20030050298-A1 | Il-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-03-13 | — | — | US | disclosed |
| EP-1272175-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1261329-A2 | IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2001072960-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
| WO-2001068033-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216375-A1 | Il-8 receptor anatagonists | CXCL8, CCR8, IL1R1 | VCAM1 153/4885CASP3 2136/4885CASP7 722/4885 |
| US-20030050298-A1 | Il-8 receptor antagonists | CXCL8, CCR8, IL1RN | VCAM1 155/4885CASP3 2651/4885CASP7 1099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.